No Data
No Data
Celldex Therapeutics Insiders Sold US$2.1m Of Shares Suggesting Hesitancy
Celldex Therapeutics to Present at Upcoming Investor Conferences
Atopic Dermatitis: 2025 Pipeline Insights Report Covering 100+ Companies and 120+ Pipeline Drugs, Including ICP-332 (Innocare Pharma), APG777 (Apogee Therapeutics), and Barzolvolimab (Celldex Therapeutics)
Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs
Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug
Celldex Therapeutics Shares Are Trading Higher After the Company Presented Preclinical Data for CDX-622 at AAAAI 2025.